Is INAB or MGX more profitable?

IN8bio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Metagenomi -384.61% -63.65% -44.52%

Do analysts rate IZTC or INAB?

IN8bio has a consensus target price of $4.00, indicating a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, IZTC or INAB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is IZTC or INAB more profitable?

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A IN8bio N/A -91.18% -76.93%

Does the media prefer IZTC or INAB?

In the previous week, IN8bio had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for IN8bio and 1 mentions for Invizyne Technologies. IN8bio's average media sentiment score of 0.57 beat Invizyne Technologies' score of 0.00 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GOSS or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% IN8bio N/A -91.18% -76.93%

Does the media favor GOSS or INAB?

In the previous week, IN8bio had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for IN8bio and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat IN8bio's score of 0.57 indicating that Gossamer Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALGS or INAB more profitable?

IN8bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. IN8bio's return on equity of -91.18% beat Aligos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -241.01% -160.72% -92.30% IN8bio N/A -91.18% -76.93%

Do analysts prefer INAB or RNAZ?

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, equities analysts clearly believe IN8bio is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, INAB or RNAZ?

IN8bio is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A

Is INAB or RNAZ more profitable?

IN8bio's return on equity of -91.18% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% TransCode Therapeutics N/A -875.35% -37.46%

Does the media prefer INAB or RNAZ?

In the previous week, IN8bio had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 5 mentions for IN8bio and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.62 beat IN8bio's score of 0.57 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IN8bio (INAB) Competitors

$1.10 +0.02 (+1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$1.09 -0.01 (-0.91%)

As of 07:30 PM Eastern

Compare

INAB vs. MGX, IZTC, GOSS, ALGS, and RNAZ

Should you buy IN8bio stock or one of its competitors? IN8bio's main competitors and comparable companies include Metagenomi (MGX), Invizyne Technologies (IZTC), Gossamer Bio (GOSS), Aligos Therapeutics (ALGS), and TransCode Therapeutics (RNAZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IN8bio compare to Metagenomi?

IN8bio (NASDAQ:INAB) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

92.1% of IN8bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

IN8bio currently has a consensus price target of $4.00, indicating a potential upside of 263.64%. Metagenomi has a consensus price target of $6.00, indicating a potential upside of 417.24%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, IN8bio had 4 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for IN8bio and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.87 beat IN8bio's score of 0.57 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Metagenomi	Very Positive

IN8bio has higher earnings, but lower revenue than Metagenomi. IN8bio is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Metagenomi	$25.21M	1.74	-$87.87M	-$2.49	N/A

IN8bio has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

IN8bio has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Metagenomi	-384.61%	-63.65%	-44.52%

Summary

Metagenomi beats IN8bio on 9 of the 15 factors compared between the two stocks.

How does IN8bio compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

In the previous week, IN8bio had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 5 mentions for IN8bio and 1 mentions for Invizyne Technologies. IN8bio's average media sentiment score of 0.57 beat Invizyne Technologies' score of 0.00 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Invizyne Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IN8bio has a consensus target price of $4.00, indicating a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Invizyne Technologies' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
IN8bio	N/A	-91.18%	-76.93%

92.1% of IN8bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

IN8bio beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

How does IN8bio compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

IN8bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
IN8bio	N/A	-91.18%	-76.93%

Gossamer Bio has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by company insiders. Comparatively, 14.5% of IN8bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

IN8bio has lower revenue, but higher earnings than Gossamer Bio. IN8bio is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.69	-$170.37M	-$0.70	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

In the previous week, IN8bio had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for IN8bio and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat IN8bio's score of 0.57 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gossamer Bio currently has a consensus target price of $3.20, indicating a potential upside of 2,147.19%. IN8bio has a consensus target price of $4.00, indicating a potential upside of 263.64%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Gossamer Bio beats IN8bio on 8 of the 14 factors compared between the two stocks.

How does IN8bio compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 622.33%. IN8bio has a consensus price target of $4.00, indicating a potential upside of 263.64%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IN8bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -241.01%. IN8bio's return on equity of -91.18% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
IN8bio	N/A	-91.18%	-76.93%

IN8bio has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.19	-$24.19M	-$7.30	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Aligos Therapeutics has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

In the previous week, IN8bio had 4 more articles in the media than Aligos Therapeutics. MarketBeat recorded 5 mentions for IN8bio and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.89 beat IN8bio's score of 0.57 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Very Positive
IN8bio	Positive

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

IN8bio beats Aligos Therapeutics on 8 of the 15 factors compared between the two stocks.

How does IN8bio compare to TransCode Therapeutics?

IN8bio (NASDAQ:INAB) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

IN8bio presently has a consensus price target of $4.00, suggesting a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, equities analysts clearly believe IN8bio is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IN8bio is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

IN8bio's return on equity of -91.18% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
TransCode Therapeutics	N/A	-875.35%	-37.46%

92.1% of IN8bio shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 0.1% of TransCode Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, IN8bio had 3 more articles in the media than TransCode Therapeutics. MarketBeat recorded 5 mentions for IN8bio and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.62 beat IN8bio's score of 0.57 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IN8bio has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

Summary

IN8bio beats TransCode Therapeutics on 9 of the 12 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.65M	$3.84B	$7.12B	$12.70B
Dividend Yield	N/A	3.61%	2.55%	9.16%
P/E Ratio	N/A	13.66	273.41	25.12
Price / Sales	N/A	1,321.98	670.91	117.13
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	0.39	15.42	10.43	6.18
Net Income	-$19.44M	-$22.82M	$3.49B	$358.18M
7 Day Performance	-5.17%	-3.59%	-2.99%	-2.34%
1 Month Performance	12.72%	0.88%	0.02%	-2.50%
1 Year Performance	-42.41%	43.89%	20.19%	9.87%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	2.7839 of 5 stars	$1.10 +1.9%	$4.00 +263.6%	-46.3%	$10.65M	N/A	N/A	20	News Coverage Short Interest Decrease
MGX Metagenomi	2.3351 of 5 stars	$1.16 -2.1%	$6.00 +419.5%	-38.2%	$43.64M	$25.21M	N/A	236
IZTC Invizyne Technologies	N/A	$6.73 -6.1%	N/A	-47.4%	$42.08M	N/A	N/A	29	News Coverage Gap Up
GOSS Gossamer Bio	2.4475 of 5 stars	$0.16 -4.3%	$3.20 +1,866.8%	-94.2%	$38.19M	$48.47M	N/A	180	Gap Down
ALGS Aligos Therapeutics	2.4993 of 5 stars	$6.02 +2.6%	$38.50 +540.1%	-51.0%	$37.53M	$2.19M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. MGX, IZTC, GOSS, ALGS, and RNAZ

How does IN8bio compare to Metagenomi?

Summary

How does IN8bio compare to Invizyne Technologies?

Summary

How does IN8bio compare to Gossamer Bio?

Summary

How does IN8bio compare to Aligos Therapeutics?

Summary

How does IN8bio compare to TransCode Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. MGX, IZTC, GOSS, ALGS, and RNAZ

How does IN8bio compare to Metagenomi?

Do insiders & institutionals have more ownership in INAB or MGX?

Do analysts rate INAB or MGX?

Does the media prefer INAB or MGX?

Which has higher earnings and valuation, INAB or MGX?

Which has more risk & volatility, INAB or MGX?

Is INAB or MGX more profitable?

Summary

How does IN8bio compare to Invizyne Technologies?

Which has higher valuation and earnings, IZTC or INAB?

Does the media prefer IZTC or INAB?

Do analysts rate IZTC or INAB?

Is IZTC or INAB more profitable?

Do institutionals and insiders believe in IZTC or INAB?

Summary

How does IN8bio compare to Gossamer Bio?

Is GOSS or INAB more profitable?

Which has more volatility and risk, GOSS or INAB?

Do institutionals & insiders hold more shares of GOSS or INAB?

Which has preferable earnings and valuation, GOSS or INAB?

Does the media favor GOSS or INAB?

Do analysts rate GOSS or INAB?

Summary

How does IN8bio compare to Aligos Therapeutics?

Do analysts prefer ALGS or INAB?

Is ALGS or INAB more profitable?

Which has stronger valuation and earnings, ALGS or INAB?

Which has more volatility and risk, ALGS or INAB?

Does the media favor ALGS or INAB?

Do institutionals and insiders have more ownership in ALGS or INAB?

Summary

How does IN8bio compare to TransCode Therapeutics?

Do analysts prefer INAB or RNAZ?

Which has stronger earnings and valuation, INAB or RNAZ?

Is INAB or RNAZ more profitable?

Do insiders & institutionals have more ownership in INAB or RNAZ?

Does the media prefer INAB or RNAZ?

Which has more volatility & risk, INAB or RNAZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools